20240010655. DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND simplified abstract (IMPACT THERAPEUTICS (SHANGHAI), INC)
Contents
DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND
Organization Name
IMPACT THERAPEUTICS (SHANGHAI), INC
Inventor(s)
Sui Xiong Cai of Shanghai (CN)
Ye Edward Tian of Shanghai (CN)
DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240010655 titled 'DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND
Simplified Explanation
The abstract of the patent application states that the compounds described in the application are wee1 kinase inhibitors. These compounds can be in the form of pharmaceutically acceptable salts or prodrugs. The abstract also mentions that the compounds can be used to treat diseases caused by abnormal wee1 activity.
- The compounds described in the patent application are wee1 kinase inhibitors.
- The compounds can exist as pharmaceutically acceptable salts or prodrugs.
- These compounds have the potential to treat diseases caused by abnormal wee1 activity.
Potential Applications
The technology described in this patent application has potential applications in the field of medicine and pharmaceuticals. Some potential applications include:
- Treatment of diseases caused by abnormal wee1 activity: The compounds described in the patent application can be used to treat diseases that are caused by abnormal wee1 activity. This opens up possibilities for developing new therapies for such diseases.
Problems Solved
The technology described in this patent application addresses the problem of diseases caused by abnormal wee1 activity. By inhibiting the activity of wee1 kinase, the compounds described in the application can potentially alleviate the symptoms and progression of these diseases.
Benefits
The technology described in this patent application offers several benefits:
- Novel treatment approach: The compounds described in the application provide a new approach to treating diseases caused by abnormal wee1 activity. This can potentially lead to more effective and targeted therapies.
- Potential for improved patient outcomes: By targeting the underlying cause of diseases, the compounds have the potential to improve patient outcomes and quality of life.
- Pharmaceutical versatility: The compounds can exist as pharmaceutically acceptable salts or prodrugs, allowing for flexibility in formulation and delivery methods.
Original Abstract Submitted
or pharmaceutically acceptable salts or prodrugs thereof, wherein the substituents are defined herein. compounds of formula i are wee1 kinase inhibitors. therefore, compounds of the invention may be used to treat diseases caused by abnormal wee1 activity.
